Validation of the international MOGAD panel proposed criteria: a single-centre US study.

Autor:	Filippatou AG; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Said Y; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Chen H; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Vasileiou ES; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.; Neurology, Mount Sinai School of Medicine, New York, New York, USA., Ahmadi G; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Sotirchos ES; Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA ess@jhmi.edu.
Jazyk:	angličtina
Zdroj:	Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Aug 16; Vol. 95 (9), pp. 870-873. Date of Electronic Publication: 2024 Aug 16.
DOI:	10.1136/jnnp-2023-333227
Abstrakt:	Background: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. We aimed to evaluate the diagnostic performance of recently proposed MOGAD diagnostic criteria in a real-world patient cohort at a tertiary referral centre. Methods: We identified all patients who were evaluated at Johns Hopkins and were MOG-IgG seropositive by cell-based assay. We retrospectively applied the proposed MOGAD diagnostic criteria. Results: Among the 122 patients included in this study, 109 fulfilled the diagnostic criteria. Of 64 patients with clear positive MOG-IgG titre, 63 patients also satisfied the supporting clinical or MRI features. Of 58 patients with low positive or unknown MOG-IgG titre, 46 met criteria by fulfilment of the supporting features. The medical records were independently reviewed by two investigators with expertise in demyelinating disease, and patients were assigned empirical clinical diagnoses, with agreement with the application of the MOGAD diagnostic criteria in the majority of cases (90%). Conclusions: Our findings support the diagnostic utility of the proposed MOGAD diagnostic criteria. Patients with MOGAD met the supporting clinical or MRI features almost universally, which suggests that the criteria can be used to accurately differentiate MOGAD from mimics with low-titre MOG-IgG seropositivity. Competing Interests: Competing interests: ESS has received speaker honoraria from Alexion and has served on scientific advisory boards for Alexion, Horizon Therapeutics, TG Therapeutics and Roche/Genentech. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu